Prosecution Insights
Prosecution Insights
Technology area: Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Prothera Biologics Inc. currently has 2 pending office actions within the Chemistry & Materials technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units, indicating a diversified prosecution landscape. This distribution suggests that the company's intellectual property covers technical aspects that fall under the jurisdiction of separate units within the patent office.
The busiest examiner for the portfolio is WALLENHORST, MAUREEN, who is managing 1 busiest examiner pending action. Since each of the 2 pending actions is handled by a different examiner, the company must navigate 2 separate sets of examiner preferences and art unit standards. This requires a varied strategy compared to a portfolio where all actions are centralized. Practitioners should monitor the progress in the 2 art units to identify any potential overlaps during the prosecution of these 2 pending matters. This distribution across 2 distinct examiners requires a coordinated effort to maintain consistency in the company's Chemistry & Materials claims.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WALLENHORST, MAUREEN | 1 | 78.9% | +5.8% |
| ORWIG, KEVIN S | 1 | 25.5% | +40.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17819591 | PREPARATION AND COMPOSITION OF INTER-ALPHA INHIBITOR PROTEINS FROM HUMAN PLASMA FOR THERAPEUTIC USE | ORWIG, KEVIN S | 16d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17819591 | PREPARATION AND COMPOSITION OF INTER-ALPHA INHIBITOR PROTEINS FROM HUMAN PLASMA FOR THERAPEUTIC USE | ORWIG, KEVIN S | 16d overdue |
| Art Unit | Apps |
|---|---|
| 1797 | 1 |
| 3991 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18036720 | METHODS FOR PURIFYING INTER-ALPHA INHIBITOR PROTEINS | WALLENHORST, MAUREEN | 1797 | §112 | Non-Final OA | — | Pending | May 12, 2023 |
| 17819591 | PREPARATION AND COMPOSITION OF INTER-ALPHA INHIBITOR PROTEINS FROM HUMAN PLASMA FOR THERAPEUTIC USE | ORWIG, KEVIN S | 3991 | §103DP | Non-Final OA | 16d overdue | Pending | Aug 12, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial